A post in Clay Siegall’s WordPress Page about the effects of Paris Accord Withdraw, says the withdrawal does not have a big effect on the production of energy in the United States. According to Robert Godby, the director of the Center for Energy Economics and Public Policy at the University of Wyoming, the decision that mattered to people in Wyoming was the one the administration agreed they do not support Clean Power Plan. Natural gas has been a preferred way of energy production because it is cheaper to use as compared to coal. This has led to the need of fewer miners of coal and people are moving out of the state to get employment. However, Robert foresees an increase in jobs in the US as technology continues to advance.
Effect of Recycling
Research recently done has shown that people tend to be more wasteful when recycling is available. According to a marketing professor at Boston University, Remi Trudel, individuals presented with recycling bags and given presents to wrap tend to use more wrapping papers unlike ones without the bag. A post in Clay Siegall’s blog says people do what makes them feel good. Shankar Vedantam, NPR social science correspondent said people feel good about recycling hence become more wasteful. Vedantam stated that in an instance where somebody has a hybrid car someone he would travel more because of how efficient it is.
Seattle Genetics fight on cancer
Clay Siegall is the co-founder and CEO of Seattle Genetics, a company that focuses on scientific innovation, rigorous research, and drug development. Mr. Siegall passion for helping cancer patients has seen him lead Seattle Genetics to develop antibody-drug conjugates for the treatment of cancer. ADCs was approved by FDA in 2011 and currently is being used in more than sixty countries. With many years of experience in research and Ph.D. in Genetics from George Washington University, Clay’s goal is to make more advancements in cancer research and cancer therapies.
Clay’s influence in Seattle Genetics
Clay Siegall has secured collaborations with the likes of Astellas and Genentech that has seen ADC technology make more three-hundred and fifty million dollars in profit to date. His company also give grants to non-profit making organizations that provide oncology and hematology support to patients.